Bluefin Capital Management’s GSK GSK Stock Holding History

Bluefin Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-179,120	Closed	-$19K	–	584
2015 Q4	$19K	Buy	+179,120	New	+$9.13M	﹤0.01%	560

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bluefin Capital Management's GSK Position: Q3 2022 in Review

Bluefin Capital Management sold out of GSK (GSK) in Q3 2022, closing a stake of 4,768 shares — an estimated $261K sold.

Bluefin Capital Management first reported a position in GSK in Q1 2014 and held it in 15 quarters. The position peaked at $2.01M in Q4 2015. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Bluefin Capital Management reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Bluefin Capital Management sold 4,768 GSK shares in Q3 2022, an estimated $261K.
Bluefin Capital Management first reported a position in GSK in Q1 2014 and held it in 15 quarters.
Bluefin Capital Management's GSK position peaked at $2.01M in Q4 2015.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Bluefin Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.